Skip to contentS
Sigyn Therapeutics, Inc.
S
SIGYSigyn Therapeutics, Inc. Q3 2022 · 10-Q
Revenue—
Net Income-$726.51K-$726.51KN/M vs Q3 2021 EPS Diluted-$0.02-$0.02N/M vs Q3 2021 Operating Income-$533,647N/M Operating Cash Flowderived-$524,167N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sigyn Therapeutics, Inc. · CIK 1642159 · Engraved from SEC EDGAR
Free Cash Flowderived-$524,168N/M ended Sep 30, 2022 · filed Nov 14, 2022 · 45 d after period end